Amedisys
AMED
AMED was delisted on the 14th of August, 2025.
286 hedge funds and large institutions have $2.79B invested in Amedisys in 2023 Q3 according to their latest regulatory filings, with 39 funds opening new positions, 90 increasing their positions, 115 reducing their positions, and 53 closing their positions.
450% more funds holding in top 10
Funds holding in top 10: 2 → 11 (+9)
2% more capital invested
Capital invested by funds: $2.74B → $2.79B (+$55.1M)
1.32% less ownership
Funds ownership: 91.96% → 90.64% (-1.3%)
5% less funds holding
Funds holding: 301 → 286 (-15)
22% less repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 115
26% less first-time investments, than exits
New positions opened: 39 | Existing positions closed: 53
93% less call options, than puts
Call options by funds: $5.97M | Put options by funds: $81.6M
Top Buyers
Top Sellers
| 1 |
DM
Deerfield Management
New York
|
-$164M |
| 2 |
RP
Riverbridge Partners
Minneapolis,
Minnesota
|
-$144M |
| 3 |
JP Morgan Chase
New York
|
-$93.6M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$55.7M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$38.3M |
AMED Hedge Fund Activity: Q3 2023 in Review
286 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Amedisys (AMED) for Q3 2023, worth a combined $2.79B — up 2% from $2.74B a quarter earlier.
Sellers outnumbered buyers: 53 funds closed out of AMED and 39 opened new positions — a net loss of 14 holders — while 115 trimmed existing stakes and 90 added.
The largest buyer was Pentwater Capital Management, adding an estimated $74.6M. The largest seller was Deerfield Management, exiting entirely with an estimated $164M sold.
- 286 institutional investors held Amedisys (AMED) as of Q3 2023, down from 301 in Q2 2023.
- Funds reported $2.79B of Amedisys stock for Q3 2023, up 2% quarter-over-quarter.
- 39 funds opened new Amedisys positions in Q3 2023 and 53 closed out, a net change of -14 holders.
- The largest Amedisys buyer in Q3 2023 was Pentwater Capital Management, an estimated $74.6M added.
- The largest Amedisys seller in Q3 2023 was Deerfield Management, an estimated $164M sold.
Based on aggregated 13F filings for Q3 2023.